Ondansetron versus dolasetron: A comparison study in the prevention of postoperative nausea and vomiting in patients undergoing gynecological procedures

AANA Journal

Volumn 72, Issue 2, 2004, Pages 129-132

  Browning, Beth A ^a   Fort, Carol A ^b   Kemp, Kevan D ^b   Shimata, Manardie F ^c   Strube, Melissa D ^b  

^a KAISER PERMANENTE   (United States)

^b Deaconess and Sacred Heart Medical Centers   (United States)

^c Ogden Regional Medical Center   (United States)

Author keywords

Antiemetics; Dolasetron; Gynecological procedures; Ondansetron; Postoperative nausea and vomiting

Indexed keywords

ANTIEMETIC AGENT; DOLASETRON MESILATE; ONDANSETRON;

ADULT; ALLERGIC REACTION; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; GYNECOLOGIC SURGERY; HEADACHE; HEART ARRHYTHMIA; HUMAN; POSTOPERATIVE NAUSEA; POSTOPERATIVE VOMITING; RANDOMIZED CONTROLLED TRIAL;

ANTIEMETICS; COST SAVINGS; DOUBLE-BLIND METHOD; DRUG COSTS; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; INCIDENCE; INDOLES; ONDANSETRON; POSTOPERATIVE NAUSEA AND VOMITING; PROSPECTIVE STUDIES; QUINOLIZINES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 1842665156     PISSN: 00946354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Domino KB, Anderson EA, Polissar NL, Posner KL. Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis. Anesth Analg. 1999;88:1370-1379.
2. Hirsch J. Impact of postoperative nausea and vomiting in the surgical setting. Anaesthesia. 1994;49(suppl):30-33.
3. Kenny GN. Risk factors for postoperative nausea and vomiting. Anaesthesia. 1994;49(suppl):6-10.
4. Diemunsch P, Leeser J, Feiss P, et al. Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting. Can J Anaesth. 1997;44:173-181.
5. Korttila K, Clergue F, Leeser J, et al. Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. Acta Anaesthesiol Scand. 1997;41:914-922.
6. Sadhasivam S, Saxena A, Kathirvel S, Kannan TR, Trikha A, Mohan V. The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy. Anesth Analg. 1999;89:1340-1345.
7. Philip BK, McLeskey CH, Chelly JE, et al. Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group. J Clin Anesth. 2000;12:1-8.
8. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology. 1992;77:162-184.
9. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst. 1991;83:613-620.
10. Sinclair DR, Chung F, Mezei G. Can postoperative nausea and vomiting be predicted? Anesthesiology. 1999;91:109-118.
11. Graczyk SG, McKenzie R, Kallar S, et al. Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery. Anesth Analg. 1997;84:325-330.
12. Kovac AL, Scuderi PE, Boerner TF, et al. Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group. Anesth Analg. 1997;85:546-552.
13. Philip BK, Pearman MH, Kovac AL, et al. Dolasetron for the prevention of postoperative nausea and vomiting following outpatient surgery with general anaesthesia: a randomized, placebo-controlled study. The Dolasetron PONV Prevention Study Group. Eur J Anaesthesiol. 2000;17:23-32.
14. Kovac A, McKenzie R, O'Connor T, et al. Prophylactic intravenous ondansetron in female outpatients undergoing gynaecological surgery: a multicentre dose-comparison study. Eur J Anaesthesiol. 1992;9(suppl 6):37-47.
15. McKenzie R, Kovac A, O'Connor T, et al. Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. Anesthesiology. 1993;78:21-28.
16. Khalil SN, Kataria B, Pearson K, et al. Ondansetron prevents postoperative nausea and vomiting in women outpatients. Anesth Analg. 1994;79:845-851.
17. Sun R, Klein KW, White PF. The effect of timing of ondansetron administration in outpatients undergoing otolaryngologic surgery. Anesth Analg. 1997;84:331-336.
18. Tang J, Wang B, White PF, Watcha MF, Qi J, Wender RH. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting. Anesth Analg. 1998;86:274-282.
19. Zarate E, Watcha MF, White PF, Klein KW, Sa Rego M, Stewart DG. A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis. Anesth Analg. 2000;90:1352-1358.
20. Scuderi PE, James RL, Harris L, Mims GR. Antiemetic prophylaxis does not improve outcomes after outpatient surgery when compared to symptomatic treatment. Anesthesiology. 1999;90:360-371.
21. Diemunsch P, D'Hollander A, Paxton L, et al. Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery. J Clin Anesth. 1997;9:365-373.
22. Kovac A, Mingus M, Sung YF, Neary M. Reduced resource utilization in patients treated for postoperative nausea and vomiting with dolasetron mesylate. MCPR44 Study Group. J Clin Anesth. 1999;11:235-241.